MarginsXMarginsX
Home › Markets › Health Care › XGN

Exagen Inc. (XGN)

XGN trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.77
-8.72% on the day
Market cap
$96.2M
Micro cap
Revenue · 2025
$66.6M
+19.7% on 2024
Net income · 2025
-$20.0M
-30.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1274737/000127473726000009/0001274737-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXGN on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO year2019
SEC CIK0001274737
SEC industry codeServices-Medical Laboratories
Incorporated inDE

Financials · 2025

LineValue
Revenue$66.6M
Net income-$20.0M
Operating income-$14.1M
Net margin-30.0%
Operating margin-21.1%
Revenue growth+19.7%
Cash$32.2M
Total assets$58.0M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
28.1 months
$28.1M cash at September 30, 2026
Share count, 1 year
+12.6%
2025-10-31 to 2026-11-03 · +49.7% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$628K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$28.1M cash; operating cash flow -$3.0M a quarter.Report 2026-09-30
Shares outstanding25,513,497 (2026-11-03); 22,663,099 a year earlier; 17,045,827 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Diego, California, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $628K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.4M-$6.3M-$2.6M$28.1M$22.8M$72.3M10-Q 2026-11-10
Q2 2026
2026-06-30
$19.9M-$3.2M$4.0M$24.6M$22.8M$71.1M10-Q 2026-08-04
Q1 2026
2026-03-31
$17.3M-$4.0M-$10.4M$21.5M$22.9M$68.4M10-Q 2026-05-11
Q4 2025
2025-12-31
$16.6M-$4.7M-$3.0M$32.2M$22.9M$66.6M10-K 2026-03-10
Q3 2025
2025-09-30
$17.2M-$7.1M$2.9M$35.7M$22.9M$63.6M10-Q 2026-11-10
Q2 2025
2025-06-30
$17.2M-$4.4M-$2.9M$30.0M$23.0M$58.9M10-Q 2026-08-04
Q1 2025
2025-03-31
$15.5M-$3.8M-$10.7M$11.2M$20.9M$56.7M10-Q 2026-05-11
Q4 2024
2024-12-31
$13.7M-$3.8M$363K$22.0M$20.2M$55.6M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-10
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 429 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-28.9%
1 month-51.3%
3 months-37.2%
Year to date-32.1%
1 year-55.8%
From 52-week high-54.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
BDSXBiodesix Inc.$9.00-8.91%$99.8M
KEQUKewaunee Scientific Corporation$35.05-1.81%$101.5M
SERASera Prognostics Inc.$1.94-3.48%$77.2M
BNRBurning Rock Biotech Limited$12.74-4.43%$134.4M
TLSITriSalus Life Sciences Inc.$2.27-6.58%$140.1M
YDESYD Bio Limited$4.83-1.02%$342.1M
MDXHMDxHealth SA$0.1490+3.40%$14.2M
FLGTFulgent Genetics Inc.$24.07-2.37%$672.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier